Anti-virulence strategies to target bacterial infections

Current Topics in Microbiology and Immunology

Volumn 398, Issue , 2016, Pages 147-183

  Mühlen, Sabrina ^a   Dersch, Petra ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLMOCIMYCIN; 2 [(4 FLUORO 3 METHYLPHENYL)SULFONYLAMINO] N HYDROXY 2 (TETRAHYDRO 2H PYRAN-4-YL)ACETAMIDE; ADHESIN; AFIMBRIAL ADHESIN; ANTIINFECTIVE AGENT; ANTIRESISTANCE DRUG; BETA LACTAMASE INHIBITOR; CATECHIN GALLATE; CYCLOSPORIN; DISPERSIN B; EFFLUX PUMP INHIBITOR; EPIGALLOCATECHIN GALLATE; FLAVONOLIGNAN; GLYCOSPHINGOLIPID; LED 209; POLYPHENOL; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REGULATORY RNA; RNA; SENSORY RNA; SORTASE; STREPTORUBIN B; UNCLASSIFIED DRUG; VALSPODAR; VIRULENCE BLOCKER; BACTERIAL PROTEIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BIOFILM; CELL COMMUNICATION; CONFORMATIONAL TRANSITION; DRUG TARGETING; ENVIRONMENTAL STRESS RESISTANCE; EXOTOXIN TRAFFICKING; FIMBRIA; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENERAL ASPECTS OF DISEASE; GENETIC PROCEDURES; GLOBAL VIRULENCE CONTROL; HOST DAMAGE; HUMAN; INFECTION CONTROL; INNATE IMMUNITY; IRON DEPLETION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUORUM SENSING; RIBOSWITCH; RNA SEQUENCE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TOXIN SYNTHESIS; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; TRANSPORT KINETICS; TRANSPOSON DIRECTED INSERTION SITE SEQUENCING; TYPE II SECRETION SYSTEM; TYPE III SECRETION SYSTEM; TYPE IV SECRETION SYSTEM; TYPE VI SECRETION SYSTEM; TYPE VII SECRETION SYSTEM; VIRULENCE GENE; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; VIRULENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; HUMANS; VIRULENCE; VIRULENCE FACTORS;

EID: 84980017599     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2015_490     Document Type: Article

References (251)

1. Aarestrup FM (2005) Veterinary drug usage and antimicrobial resistance in bacteria of animal origin. Basic Clin Pharmacol Toxicol 96:271-281.
2. Ackermann M (2015) A functional perspective on phenotypic heterogeneity in microorganisms. Nat Rev Microbiol 13:497-508.
3. Aggarwal C, Jimenez JC, Lee H, Chlipala GE, Ratia K, Federle MJ (2015) Identification of quorum-sensing inhibitors disrupting signaling between Rgg and short hydrophobic peptides in Streptococci. MBio 6:e00393-e00315.
4. Allen HK, Donato J, Wang HH, Cloud-Hansen KA, Davies J, Handelsman J (2010) Call of the wild: antibiotic resistance genes in natural environments. Nat Rev Microbiol 8:251-259.
5. Altier C, Suyemoto M, Ruiz AI, Burnham KD, Maurer R (2000) Characterization of two novel regulatory genes affecting Salmonella invasion gene expression. Mol Microbiol 35:635-646.
6. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:462-471.
7. Arya R, Princy SA (2013) An insight into pleiotropic regulators Agr and Sar: molecular probes paving the new way for antivirulent therapy. Future Microbiol 8:1339-1353.
8. Avery SV (2006) Microbial cell individuality and the underlying sources of heterogeneity. Nat Rev Microbiol 4:577-587.
9. Bailey L, Gylfe A, Sundin C, Muschiol S, Elofsson M, Nordstrom P, Henriques-Normark B, Lugert R, Waldenstrom A, Wolf-Watz H et al (2007) Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett 581:587-595.
10. Baldari CT, Tonello F, Paccani SR, Montecucco C (2006) Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol 27:434-440.
11. Bannwarth L, Goldberg AB, Chen C, Turk BE (2012) Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening. Chem Biol 19:875-882.
12. Barnhart MM, Sauer FG, Pinkner JS, Hultgren SJ (2003) Chaperone-subunit-usher interactions required for donor strand exchange during bacterial pilus assembly. J Bacteriol 185:2723-2730.
13. Baron C (2010) Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol 13:100-105.
14. Barraud N, Hassett DJ, Hwang SH, Rice SA, Kjelleberg S, Webb JS (2006) Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 188:7344-7353.
15. Barraud N, Schleheck D, Klebensberger J, Webb JS, Hassett DJ, Rice SA, Kjelleberg S (2009) Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol 191:7333-7342.
16. Basha S, Rai P, Poon V, Saraph A, Gujraty K, Go MY, Sadacharan S, Frost M, Mogridge J, Kane RS (2006) Polyvalent inhibitors of anthrax toxin that target host receptors. Proc Natl Acad Sci USA 103:13509-13513.
17. Beckham KS, Roe AJ (2014) From screen to target: insights and approaches for the development of anti-virulence compounds. Front Cell Infect Microbiol 4:139.
18. Berendonk TU, Manaia CM, Merlin C, Fatta-Kassinos D, Cytryn E, Walsh F, Burgmann H, Sorum H, Norstrom M, Pons MN et al (2015) Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol 13:310-317.
19. Bierne H, Mazmanian SK, Trost M, Pucciarelli MG, Liu G, Dehoux P, Jansch L, Garcia-del Portillo F, Schneewind O, Cossart P et al (2002) Inactivation of the srtA gene in Listeria monocytogenes inhibits anchoring of surface proteins and affects virulence. Mol Microbiol 43:869-881.
20. Bliska JB, Wang X, Viboud GI, Brodsky IE (2013) Modulation of innate immune responses by Yersinia type III secretion system translocators and effectors. Cell Microbiol 15:1622-1631.
21. Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, Imbriglio J, Young K, Park YW, Ogawa A et al (2014) Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin(R). Bioorg Med Chem Lett 24:780-785.
22. Böhme K, Steinmann R, Kortmann J, Seekircher S, Heroven AK, Berger E, Pisano F, Thiermann T, Wolf-Watz H, Narberhaus F et al (2012) Concerted actions of a thermo-labile regulator and a unique intergenic RNA thermosensor control Yersinia virulence. PLoS Pathog 8:e1002518.
23. Bohnert JA, Kern WV (2005) Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 49:849-852.
24. Bowser TE, Bartlett VJ, Grier MC, Verma AK, Warchol T, Levy SB, Alekshun MN (2007) Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors. Bioorg Med Chem Lett 17:5652-5655.
25. Boyd B, Lingwood C (1989) Verotoxin receptor glycolipid in human renal tissue. Nephron 51:207-210.
26. Brautaset T, Lale R, Valla S (2009) Positively regulated bacterial expression systems. Microb Biotechnol 2:15-30.
27. Brown HL, Hanman K, Reuter M, Betts RP, van Vliet AH (2015) Campylobacter jejuni biofilms contain extracellular DNA and are sensitive to DNase I treatment. Front Microbiol 6:699.
28. Bruckner R, Titgemeyer F (2002) Carbon catabolite repression in bacteria: choice of the carbon source and autoregulatory limitation of sugar utilization. FEMS Microbiol Lett 209:141-148.
29. Burton NA, Schurmann N, Casse O, Steeb AK, Claudi B, Zankl J, Schmidt A, Bumann D (2014) Disparate impact of oxidative host defenses determines the fate of Salmonella during systemic infection in mice. Cell Host Microbe 15:72-83.
30. Canton R (2009) Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. Clin Microbiol Infect 15(Suppl 1):20-25.
31. Carlier M, Carrette S, Stove V, Verstraete AG, De Waele JJ (2014) Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents 43:470-473.
32. Cascioferro S, Totsika M, Schillaci D (2014) Sortase A: an ideal target for anti-virulence drug development. Microb Pathog 77:105-112.
33. Cascioferro S, Raffa D, Maggio B, Raimondi MV, Schillaci D, Daidone G (2015) Sortase A inhibitors: recent advances and future perspectives. J Med Chem.
34. Castanheira M, Williams G, Jones RN, Sader HS (2014) Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying beta-lactamases prevalent in the United States. Microb Drug Resist 20:436-440.
35. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ (2008) The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 6:17-27.
36. Chan AH, Wereszczynski J, Amer BR, Yi SW, Jung ME, McCammon JA, Clubb RT (2013) Discovery of Staphylococcus aureus sortase A inhibitors using virtual screening and the relaxed complex scheme. Chem Biol Drug Des 82:418-428.
37. Chandran V (2013) Type IV secretion machinery: molecular architecture and function. Biochem Soc Trans 41:17-28.
38. Chao Y, Vogel J (2010) The role of Hfq in bacterial pathogens. Curr Opin Microbiol 13:24-33.
39. Chaudhuri RR, Morgan E, Peters SE, Pleasance SJ, Hudson DL, Davies HM, Wang J, van Diemen PM, Buckley AM, Bowen AJ et al (2013) Comprehensive assignment of roles for Salmonella typhimurium genes in intestinal colonization of food-producing animals. PLoS Genet 9:e1003456.
40. Chen Z, Moayeri M, Purcell R (2011) Monoclonal antibody therapies against anthrax. Toxins (Basel) 3:1004-1019.
41. Chhabra SR, Stead P, Bainton NJ, Salmond GP, Stewart GS, Williams P, Bycroft BW (1993) Autoregulation of carbapenem biosynthesis in Erwinia carotovora by analogues of N-(3-oxohexanoyl)-L-homoserine lactone. J Antibiot (Tokyo) 46:441-454.
42. Clarke DJ (2010) The Rcs phosphorelay: more than just a two-component pathway. Future Microbiol 5:1173-1184.
43. Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3:541-548.
44. Claudi B, Sprote P, Chirkova A, Personnic N, Zankl J, Schurmann N, Schmidt A, Bumann D (2014) Phenotypic variation of Salmonella in host tissues delays eradication by antimicrobial chemotherapy. Cell 158:722-733.
45. Coban AY, Tanriverdi Cayci Y, Erturan Z, Durupinar B (2009) Effects of efflux pump inhibitors phenyl-arginine-beta-naphthylamide and 1-(1-naphthylmethyl)-piperazine on the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Chemother 21:592-594.
46. Coburn B, Sekirov I, Finlay BB (2007) Type III secretion systems and disease. Clin Microbiol Rev 20:535-549.
47. Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW (2014) Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 58:3366-3372.
48. Conover MS, Mishra M, Deora R (2011) Extracellular DNA is essential for maintaining Bordetella biofilm integrity on abiotic surfaces and in the upper respiratory tract of mice. PLoS ONE 6: e16861.
49. Control CfD (2013) Antibiotic resistance threats in the United States.
50. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
51. Cryan LM, Rogers MS (2011) Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed) 16:1574-1588.
52. Cryan LM, Habeshian KA, Caldwell TP, Morris MT, Ackroyd PC, Christensen KA, Rogers MS (2013) Identification of small molecules that inhibit the interaction of TEM8 with anthrax protective antigen using a FRET assay. J Biomol Screen 18:714-725.
53. Curtis MM, Russell R, Moreira CG, Adebesin AM, Wang C, Williams NS, Taussig R, Stewart D, Zimmern P, Lu B et al (2014) QseC inhibitors as an antivirulence approach for Gram-negative pathogens. MBio 5:e02165.
54. D’Costa VM, McGrann KM, Hughes DW, Wright GD (2006) Sampling the antibiotic resistome. Science 311:374-377.
55. Deep A, Chaudhary U, Gupta V (2011) Quorum sensing and bacterial pathogenicity: from molecules to disease. J Lab Phys 3:4-11.
56. Dell’Aica I, Dona M, Tonello F, Piris A, Mock M, Montecucco C, Garbisa S (2004) Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep 5:418-422.
57. Desroy N, Denis A, Oliveira C, Atamanyuk D, Briet S, Faivre F, LeFralliec G, Bonvin Y, Oxoby M, Escaich S et al (2013) Novel HldE-K inhibitors leading to attenuated Gram negative bacterial virulence. J Med Chem 56:1418-1430.
58. Deutscher J, Herro R, Bourand A, Mijakovic I, Poncet S (2005) P-Ser-HPr-a link between carbon metabolism and the virulence of some pathogenic bacteria. Biochim Biophys Acta 1754:118-125.
59. Diard M, Garcia V, Maier L, Remus-Emsermann MN, Regoes RR, Ackermann M, Hardt WD (2013) Stabilization of cooperative virulence by the expression of an avirulent phenotype. Nature 494:353-356.
60. Dong YH, Xu JL, Li XZ, Zhang LH (2000) AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. Proc Natl Acad Sci USA 97:3526-3531.
61. Dong YH, Wang LH, Xu JL, Zhang HB, Zhang XF, Zhang LH (2001) Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature 411:813-817.
62. Dong YH, Gusti AR, Zhang Q, Xu JL, Zhang LH (2002) Identification of quorum-quenching N-acyl homoserine lactonases from Bacillus species. Appl Environ Microbiol 68:1754-1759.
63. Duncan MC, Wong WR, Dupzyk AJ, Bray WM, Linington RG, Auerbuch V (2014) An NF-kappaB-based high-throughput screen identifies piericidins as inhibitors of the Yersinia pseudotuberculosis type III secretion system. Antimicrob Agents Chemother 58:1118-1126.
64. Duss O, Michel E, Yulikov M, Schubert M, Jeschke G, Allain FH (2014) Structural basis of the non-coding RNA RsmZ acting as a protein sponge. Nature 509:588-592.
65. Escaich S (2008) Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 12:400-408.
66. Escaich S (2010) Novel agents to inhibit microbial virulence and pathogenicity. Expert Opin Ther Pat 20:1401-1418.
67. Felise HB, Nguyen HV, Pfuetzner RA, Barry KC, Jackson SR, Blanc MP, Bronstein PA, Kline T, Miller SI (2008) An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 4:325-336.
68. Feng L, Rutherford ST, Papenfort K, Bagert JD, van Kessel JC, Tirrell DA, Wingreen NS, Bassler BL (2015) A qrr noncoding RNA deploys four different regulatory mechanisms to optimize quorum-sensing dynamics. Cell 160:228-240.
69. Fernicola S, Paiardini A, Giardina G, Rampioni G, Leoni L, Cutruzzola F, Rinaldo S (2015) In silico discovery and in vitro validation of catechol-containing sulfonohydrazide compounds as potent inhibitors of the diguanylate cyclase PleD. J Bacteriol.
70. Ferreras JA, Ryu JS, Di Lello F, Tan DS, Quadri LE (2005) Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia pestis. Nat Chem Biol 1:29-32.
71. Field M (2003) Intestinal ion transport and the pathophysiology of diarrhea. J Clin Invest 111:931-943.
72. Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N (1987) Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect Immun 55:472-476.
73. Forst SA, Roberts DL (1994) Signal transduction by the EnvZ-OmpR phosphotransfer system in bacteria. Res Microbiol 145:363-373.
74. Francois B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A et al (2012) Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 40:2320-2326.
75. Galan JE, Wolf-Watz H (2006) Protein delivery into eukaryotic cells by type III secretion machines. Nature 444:567-573.
76. Garrity-Ryan LK, Kim OK, Balada-Llasat JM, Bartlett VJ, Verma AK, Fisher ML, Castillo C, Songsungthong W, Tanaka SK, Levy SB et al (2010) Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model. Infect Immun 78:4683-4690.
77. Goldman ME, Cregar L, Nguyen D, Simo O, O’Malley S, Humphreys T (2006) Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacol 6:8.
78. Greener M (2000) How Escherichia coli kills. Mol Med Today 6:411.
79. Groisman EA, Mouslim C (2006) Sensing by bacterial regulatory systems in host and non-host environments. Nat Rev Microbiol 4:705-709.
80. Gu J, Ning Y, Wang H, Xiao D, Tang B, Luo P, Cheng Y, Jiang M, Li N, Zou Q et al (2011) Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice. Vaccine 29:7395-7403.
81. Hall-Stoodley L, Costerton JW, Stoodley P (2004) Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2:95-108.
82. Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, Ellenberger T, Cusumano CK, Hultgren SJ et al (2010) Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53:4779-4792.
83. Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW (2012) Lead optimization studies on FimH antagonists: discovery of potent and orally bio-available ortho-substituted biphenyl mannosides. J Med Chem 55:3945-3959.
84. Harmon DE, Davis AJ, Castillo C, Mecsas J (2010) Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis. Antimicrob Agents Chemother 54:3241-3254.
85. Harmsen M, Lappann M, Knochel S, Molin S (2010) Role of extracellular DNA during biofilm formation by Listeria monocytogenes. Appl Environ Microbiol 76:2271-2279.
86. Hartmann M, Papavlassopoulos H, Chandrasekaran V, Grabosch C, Beiroth F, Lindhorst TK, Rohl C (2012) Inhibition of bacterial adhesion to live human cells: activity and cytotoxicity of synthetic mannosides. FEBS Lett 586:1459-1465.
87. Helaine S, Cheverton AM, Watson KG, Faure LM, Matthews SA, Holden DW (2014) Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science 343:204-208.
88. Henkel JS, Baldwin MR, Barbieri JT (2010) Toxins from bacteria. EXS 100:1-29.
89. Hentzer M, Givskov M (2003) Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J Clin Invest 112:1300-1307.
90. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, Parsek MR, Rice SA, Eberl L, Molin S, Hoiby N et al (2002) Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148:87-102.
91. Heroven AK, Böhme K, Dersch P (2012) The Csr/Rsm system of Yersinia and related pathogens: a post-transcriptional strategy for managing virulence. RNA Biol 9:379-391.
92. Hesterkamp T (2015) Antibiotics clinical development and pipeline. Curr Top Microbiol Immunol.
93. Hilleringmann M, Pansegrau W, Doyle M, Kaufman S, MacKichan ML, Gianfaldoni C, Ruggiero P, Covacci A (2006) Inhibitors of Helicobacter pylori ATPase Cagalpha block CagA transport and cag virulence. Microbiology 152:2919-2930.
94. Hopwood DA (2007) How do antibiotic-producing bacteria ensure their self-resistance before antibiotic biosynthesis incapacitates them? Mol Microbiol 63:937-940.
95. Hudson DL, Layton AN, Field TR, Bowen AJ, Wolf-Watz H, Elofsson M, Stevens MP, Galyov EE (2007) Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob Agents Chemother 51:2631-2635.
96. Hueck CJ (1998) Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 62:379-433.
97. Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ (2005) Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310:670-674.
98. Iwatsuki M, Uchida R, Yoshijima H, Ui H, Shiomi K, Kim YP, Hirose T, Sunazuka T, Abe A, Tomoda H et al (2008) Guadinomines, type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. II: physico-chemical properties and structure elucidation. J Antibiot (Tokyo) 61:230-236.
99. Izano EA, Amarante MA, Kher WB, Kaplan JB (2008) Differential roles of poly-N-acetylglucosamine surface polysaccharide and extracellular DNA in Staphylococcus aureus and Staphylococcus epidermidis biofilms. Appl Environ Microbiol 74:470-476.
100. Izore T, Job V, Dessen A (2011) Biogenesis, regulation, and targeting of the type III secretion system. Structure 19:603-612.
101. Jeon B, Zhang Q (2009) Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter. J Antimicrob Chemother 63:946-948.
102. Johansson J, Mandin P, Renzoni A, Chiaruttini C, Springer M, Cossart P (2002) An RNA thermosensor controls expression of virulence genes in Listeria monocytogenes. Cell 110:551-561.
103. Jonsson IM, Mazmanian SK, Schneewind O, Verdrengh M, Bremell T, Tarkowski A (2002) On the role of Staphylococcus aureus sortase and sortase-catalyzed surface protein anchoring in murine septic arthritis. J Infect Dis 185:1417-1424.
104. Kalia NP, Mahajan P, Mehra R, Nargotra A, Sharma JP, Koul S, Khan IA (2012) Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus. J Antimicrob Chemother 67:2401-2408.
105. Kaplan BS, Meyers KE, Schulman SL (1998) The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol 9:1126-1133.
106. Kaplan JB, Velliyagounder K, Ragunath C, Rohde H, Mack D, Knobloch JK, Ramasubbu N (2004) Genes involved in the synthesis and degradation of matrix polysaccharide in Actinobacillus actinomycetemcomitans and Actinobacillus pleuropneumoniae biofilms. J Bacteriol 186:8213-8220.
107. Karginov VA, Yohannes A, Robinson TM, Fahmi NE, Alibek K, Hecht SM (2006) Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin. Bioorg Med Chem 14:33-40.
108. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M (2003) Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 10:241-249.
109. Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA (2006) Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 57:339-343.
110. Keyser P, Elofsson M, Rosell S, Wolf-Watz H (2008) Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. J Intern Med 264:17-29.
111. Kim OK, Garrity-Ryan LK, Bartlett VJ, Grier MC, Verma AK, Medjanis G, Donatelli JE, Macone AB, Tanaka SK, Levy SB et al (2009) N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. J Med Chem 52:5626-5634.
112. Kim S, Jiao GS, Moayeri M, Crown D, Cregar-Hernandez L, McKasson L, Margosiak SA, Leppla SH, Johnson AT (2011) Antidotes to anthrax lethal factor intoxication. Part 2: structural modifications leading to improved in vivo efficacy. Bioorg Med Chem Lett 21:2030-2033.
113. Kimura K, Iwatsuki M, Nagai T, Matsumoto A, Takahashi Y, Shiomi K, Omura S, Abe A (2011) A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J Antibiot (Tokyo) 64:197-203.
114. Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, Ling H, Pannu NS, Read RJ, Bundle DR (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403:669-672.
115. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Luthi C, Scharenberg M, Bezencon J et al (2010) FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 53:8627-8641.
116. Kline T, Bowman J, Iglewski BH, de Kievit T, Kakai Y, Passador L (1999) Novel synthetic analogs of the Pseudomonas autoinducer. Bioorg Med Chem Lett 9:3447-3452.
117. Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R (2010) D-amino acids trigger biofilm disassembly. Science 328:627-629.
118. Kolodkin-Gal I, Cao S, Chai L, Bottcher T, Kolter R, Clardy J, Losick R (2012) A self-produced trigger for biofilm disassembly that targets exopolysaccharide. Cell 149:684-692.
119. Kong KF, Schneper L, Mathee K (2010) Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS 118:1-36.
120. Koppolu V, Osaka I, Skredenske JM, Kettle B, Hefty PS, Li J, Egan SM (2013) Small-molecule inhibitor of the Shigella flexneri master virulence regulator VirF. Infect Immun 81:4220-4231.
121. Kortmann J, Narberhaus F (2012) Bacterial RNA thermometers: molecular zippers and switches. Nat Rev Microbiol 10:255-265.
122. Krachler AM, Orth K (2013) Targeting the bacteria-host interface: strategies in anti-adhesion therapy. Virulence 4:284-294.
123. Kulkarni AA, Fuller C, Korman H, Weiss AA, Iyer SS (2010) Glycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2. Bioconjug Chem 21:1486-1493.
124. Kulp A, Kuehn MJ (2010) Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol 64:163-184.
125. Kunsmann L, Ruter C, Bauwens A, Greune L, Gluder M, Kemper B, Fruth A, Wai SN, He X, Lloubes R et al (2015) Virulence from vesicles: novel mechanisms of host cell injury by Escherichia coli O104: H4 outbreak strain. Sci Rep 5:13252.
126. Kuzmic P, Cregar L, Millis SZ, Goldman M (2006) Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides. FEBS J 273:3054-3062.
127. Langridge GC, Phan MD, Turner DJ, Perkins TT, Parts L, Haase J, Charles I, Maskell DJ, Peters SE, Dougan G et al (2009) Simultaneous assay of every Salmonella Typhi gene using one million transposon mutants. Genome Res 19:2308-2316.
128. LaSarre B, Federle MJ (2013) Exploiting quorum sensing to confuse bacterial pathogens. Microbiol Mol Biol Rev 77:73-111.
129. Layton AN, Hudson DL, Thompson A, Hinton JC, Stevens JM, Galyov EE, Stevens MP (2010) Salicylidene acylhydrazide-mediated inhibition of type III secretion system-1 in Salmonella enterica serovar Typhimurium is associated with iron restriction and can be reversed by free iron. FEMS Microbiol Lett 302:114-122.
130. Lee B, Boucher HW (2015) Targeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to ‘get smart’. Curr Opin Pulm Med 21:293-303.
131. Lehner T, Caldwell J, Smith R (1985) Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries. Infect Immun 50:796-799.
132. Lewis K (2005) Persister cells and the riddle of biofilm survival. Biochemistry (Mosc) 70:267-274.
133. Lewis K (2008) Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107-131.
134. Li H, Qian L, Chen Z, Thibault D, Liu G, Liu T, Thanassi DG (2004) The outer membrane usher forms a twin-pore secretion complex. J Mol Biol 344:1397-1407.
135. Linden SK, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, Sutton P, McGuckin MA (2009) MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog 5:e1000617.
136. Linington RG, Robertson M, Gauthier A, Finlay BB, van Soest R, Andersen RJ (2002) Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Org Lett 4:4089-4092.
137. Loh E, Kugelberg E, Tracy A, Zhang Q, Gollan B, Ewles H, Chalmers R, Pelicic V, Tang CM (2013) Temperature triggers immune evasion by Neisseria meningitidis. Nature 502:237-240.
138. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T et al (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45:105-116.
139. Lu TK, Collins JJ (2007) Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci USA 104:11197-11202.
140. Lu C, Maurer CK, Kirsch B, Steinbach A, Hartmann RW (2014a) Overcoming the unexpected functional inversion of a PqsR antagonist in Pseudomonas aeruginosa: an in vivo potent antivirulence agent targeting pqs quorum sensing. Angew Chem Int Ed Engl 53:1109-1112.
141. Lu C, Kirsch B, Maurer CK, de Jong JC, Braunshausen A, Steinbach A, Hartmann RW (2014b) Optimization of anti-virulence PqsR antagonists regarding aqueous solubility and biological properties resulting in new insights in structure-activity relationships. Eur J Med Chem 79:173-183.
142. Lucchetti-Miganeh C, Burrowes E, Baysse C, Ermel G (2008) The post-transcriptional regulator CsrA plays a central role in the adaptation of bacterial pathogens to different stages of infection in animal hosts. Microbiology 154:16-29.
143. Lynch SV, Wiener-Kronish JP (2008) Novel strategies to combat bacterial virulence. Curr Opin Crit Care 14:593-599.
144. Ma JK, Hunjan M, Smith R, Lehner T (1989) Specificity of monoclonal antibodies in local passive immunization against Streptococcus mutans. Clin Exp Immunol 77:331-337.
145. Madsen JS, Burmolle M, Hansen LH, Sorensen SJ (2012) The interconnection between biofilm formation and horizontal gene transfer. FEMS Immunol Med Microbiol 65:183-195.
146. Manefield M, de Nys R, Kumar N, Read R, Givskov M, Steinberg P, Kjelleberg S (1999) Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein. Microbiology 145(2):283-291.
147. Manina G, Dhar N, McKinney JD (2015) Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms. Cell Host Microbe 17:32-46.
148. Maresso AW, Wu R, Kern JW, Zhang R, Janik D, Missiakas DM, Duban ME, Joachimiak A, Schneewind O (2007) Activation of inhibitors by sortase triggers irreversible modification of the active site. J Biol Chem 282:23129-23139.
149. Margalit M, Ash N, Zimran A, Halkin H (2002) Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher’s disease. Postgrad Med J 78:564-565.
150. Marshall NC, Finlay BB (2014) Targeting the type III secretion system to treat bacterial infections. Expert Opin Ther Targets 18:137-152.
151. Martinez JL, Fajardo A, Garmendia L, Hernandez A, Linares JF, Martinez-Solano L, Sanchez MB (2009) A global view of antibiotic resistance. FEMS Microbiol Rev 33:44-65.
152. McHugh SM, Hill AD, Humphreys H (2010) Preventing healthcare-associated infection through education: have surgeons been overlooked? Surgeon 8:96-100.
153. McShan AC, De Guzman RN (2015) The bacterial type III secretion system as a target for developing new antibiotics. Chem Biol Drug Des 85:30-42.
154. Mellin JR, Tiensuu T, Becavin C, Gouin E, Johansson J, Cossart P (2013) A riboswitch-regulated antisense RNA in Listeria monocytogenes. Proc Natl Acad Sci USA 110:13132-13137.
155. Mellin JR, Koutero M, Dar D, Nahori MA, Sorek R, Cossart P (2014) Riboswitches. Sequestration of a two-component response regulator by a riboswitch-regulated noncoding RNA. Science 345:940-943.
156. Miethke M, Marahiel MA (2007) Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 71:413-451.
157. Montecucco C, Tonello F, Zanotti G (2004) Stop the killer: how to inhibit the anthrax lethal factor metalloprotease. Trends Biochem Sci 29:282-285.
158. Mu Y, Shen Z, Jeon B, Dai L, Zhang Q (2013) Synergistic effects of anti-CmeA and anti-CmeB peptide nucleic acids on sensitizing Campylobacter jejuni to antibiotics. Antimicrob Agents Chemother 57:4575-4577.
159. Muschiol S, Bailey L, Gylfe A, Sundin C, Hultenby K, Bergstrom S, Elofsson M, Wolf-Watz H, Normark S, Henriques-Normark B (2006) A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci USA 103:14566-14571.
160. Nagai H, Kubori T (2011) Type IVB secretion systems of Legionella and other Gram-negative bacteria. Front Microbiol 2:136.
161. Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H, Rhen M (2007) Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 51:2867-2876.
162. Neres J, Labello NP, Somu RV, Boshoff HI, Wilson DJ, Vannada J, Chen L, Barry CE 3rd, Bennett EM, Aldrich CC (2008) Inhibition of siderophore biosynthesis in Mycobacterium tuberculosis with nucleoside bisubstrate analogues: structure-activity relationships of the nucleobase domain of 5’-O-[N-(salicyl)sulfamoyl] adenosine. J Med Chem 51:5349-5370.
163. Nestorovich EM, Bezrukov SM (2014) Designing inhibitors of anthrax toxin. Expert Opin Drug Discov 9:299-318.
164. Ng WL, Bassler BL (2009) Bacterial quorum-sensing network architectures. Annu Rev Genet 43:197-222.
165. Nikaido H, Pages JM (2012) Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 36:340-363.
166. Nishikawa K, Matsuoka K, Watanabe M, Igai K, Hino K, Hatano K, Yamada A, Abe N, Terunuma D, Kuzuhara H et al (2005) Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 191:2097-2105.
167. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M (2005) Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 73:3104-3114.
168. Nuss AM, Heroven AK, Waldmann B, Reinkensmeier J, Jarek M, Beckstette M, Dersch P (2015) Trans-criptomic profiling of Yersinia pseudotuberculosis reveals reprogramming of the Crp regulon by temperature and uncovers Crp as a master regulator of small RNAs. PLoS Genet 11: e1005087.
169. O’Connell KM, Hodgkinson JT, Sore HF, Welch M, Salmond GP, Spring DR (2013) Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials. Angew Chem Int Ed Engl 52:10706-10733.
170. Ofek I, Hasty DL, Sharon N (2003) Anti-adhesion therapy of bacterial diseases: prospects and problems. FEMS Immunol Med Microbiol 38:181-191.
171. Okshevsky M, Regina VR, Meyer RL (2015) Extracellular DNA as a target for biofilm control. Curr Opin Biotechnol 33:73-80.
172. Oliva G, Sahr T, Buchrieser C (2015) Small RNAs, 5′ UTR elements and RNA-binding proteins in intracellular bacteria: impact on metabolism and virulence. FEMS Microbiol Rev 39:331-349.
173. Palzkill T (2013) Metallo-beta-lactamase structure and function. Ann N Y Acad Sci 1277:91-104.
174. Pan NJ, Brady MJ, Leong JM, Goguen JD (2009) Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother 53:385-392.
175. Panchal RG, Hermone AR, Nguyen TL, Wong TY, Schwarzenbacher R, Schmidt J, Lane D, McGrath C, Turk BE, Burnett J et al (2004) Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol 11:67-72.
176. Pannek S, Higgins PG, Steinke P, Jonas D, Akova M, Bohnert JA, Seifert H, Kern WV (2006) Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J Antimicrob Chemother 57:970-974.
177. Papenfort K, Vogel J (2014) Small RNA functions in carbon metabolism and virulence of enteric pathogens. Front Cell Infect Microbiol 4:91.
178. Park S, Kim HS, Ok K, Kim Y, Park HD, Byun Y (2015) Design, synthesis and biological evaluation of 4-(alkyloxy)-6-methyl-2H-pyran-2-one derivatives as quorum sensing inhibitors. Bioorg Med Chem Lett 25:2913-2917.
179. Parker P, Sando L, Pearson R, Kongsuwan K, Tellam RL, Smith S (2010) Bovine Muc1 inhibits binding of enteric bacteria to Caco-2 cells. Glycoconj J 27:89-97.
180. Parsek MR, Val DL, Hanzelka BL, Cronan JE Jr., Greenberg EP (1999) Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci USA 96:4360-4365.
181. Paschos A, den Hartigh A, Smith MA, Atluri VL, Sivanesan D, Tsolis RM, Baron C (2011) An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. Infect Immun 79:1033-1043.
182. Paulasova P, Pellestor F (2004) The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses. Ann Genet 47:349-358.
183. Pearson JS, Zhang Y, Newton HJ, Hartland EL (2015) Post-modern pathogens: surprising activities of translocated effectors from E. coli and Legionella. Curr Opin Microbiol 23:73-79.
184. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F (1999) Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274:8405-8410.
185. Peselis A, Serganov A (2014) Themes and variations in riboswitch structure and function. Biochim Biophys Acta 1839:908-918.
186. Pinkner JS, Remaut H, Buelens F, Miller E, Aberg V, Pemberton N, Hedenstrom M, Larsson A, Seed P, Waksman G et al (2006) Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc Natl Acad Sci USA 103:17897-17902.
187. Putrins M, Kogermann K, Lukk E, Lippus M, Varik V, Tenson T (2015) Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement. Infect Immun 83:1056-1067.
188. Qin Z, Ou Y, Yang L, Zhu Y, Tolker-Nielsen T, Molin S, Qu D (2007) Role of autolysin-mediated DNA release in biofilm formation of Staphylococcus epidermidis. Microbiology 153:2083-2092.
189. Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117-128.
190. Rasko DA, Moreira CG, de Li R, Reading NC, Ritchie JM, Waldor MK, Williams N, Taussig R, Wei S, Roth M et al (2008) Targeting QseC signaling and virulence for antibiotic development. Science 321:1078-1080.
191. Renau TE, Leger R, Flamme EM, Sangalang J, She MW, Yen R, Gannon CL, Griffith D, Chamberland S, Lomovskaya O et al (1999) Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem 42:4928-4931.
192. Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079-1081.
193. Rogers MS, Cryan LM, Habeshian KA, Bazinet L, Caldwell TP, Ackroyd PC, Christensen KA (2012) A FRET-based high throughput screening assay to identify inhibitors of anthrax protective antigen binding to capillary morphogenesis gene 2 protein. PLoS ONE 7:e39911.
194. Romeo T, Vakulskas CA, Babitzke P (2013) Post-transcriptional regulation on a global scale: form and function of Csr/Rsm systems. Environ Microbiol 15:313-324.
195. Romling U, Balsalobre C (2012) Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med 272:541-561.
196. Saar-Dover R, Bitler A, Nezer R, Shmuel-Galia L, Firon A, Shimoni E, Trieu-Cuot P, Shai Y (2012) D-alanylation of lipoteichoic acids confers resistance to cationic peptides in group B streptococcus by increasing the cell wall density. PLoS Pathog 8:e1002891.
197. Salyers AA, Gupta A, Wang Y (2004) Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 12:412-416.
198. Santa Maria JP Jr, Sadaka A, Moussa SH, Brown S, Zhang YJ, Rubin EJ, Gilmore MS, Walker S (2014) Compound-gene interaction mapping reveals distinct roles for Staphylococcus aureus teichoic acids. Proc Natl Acad Sci USA 111:12510-12515.
199. Schmitt CK, Meysick KC, O’Brien AD (1999) Bacterial toxins: friends or foes? Emerg Infect Dis 5:224-234.
200. Schroeder GN, Hilbi H (2008) Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev 21:134-156.
201. Schumacher A, Steinke P, Bohnert JA, Akova M, Jonas D, Kern WV (2006) Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemother 57:344-348.
202. Scobie HM, Thomas D, Marlett JM, Destito G, Wigelsworth DJ, Collier RJ, Young JA, Manchester M (2005) A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J Infect Dis 192:1047-1051.
203. Serganov A, Nudler E (2013) A decade of riboswitches. Cell 152:17-24.
204. Shakhnovich EA, Hung DT, Pierson E, Lee K, Mekalanos JJ (2007) Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci USA 104:2372-2377.
205. Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Felcetto T, Michael BF, Bansal A, Cummings RT et al (2005) Anthrax lethal factor inhibition. Proc Natl Acad Sci USA 102:7958-7963.
206. Silberstein C, Lucero MS, Zotta E, Copeland DP, Lingyun L, Repetto HA, Ibarra C (2011) A glucosylceramide synthase inhibitor protects rats against the cytotoxic effects of shiga toxin 2. Pediatr Res 69:390-394.
207. Skredenske JM, Koppolu V, Kolin A, Deng J, Kettle B, Taylor B, Egan SM (2013) Identification of a small-molecule inhibitor of bacterial AraC family activators. J Biomol Screen 18:588-598.
208. Slepenkin A, Enquist PA, Hagglund U, de la Maza LM, Elofsson M, Peterson EM (2007) Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun 75:3478-3489.
209. Smith KM, Bu Y, Suga H (2003a) Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthetic autoinducer analogs. Chem Biol 10:81-89.
210. Smith KM, Bu Y, Suga H (2003b) Library screening for synthetic agonists and antagonists of a Pseudomonas aeruginosa autoinducer. Chem Biol 10:563-571.
211. Smits WK, Kuipers OP, Veening JW (2006) Phenotypic variation in bacteria: the role of feedback regulation. Nat Rev Microbiol 4:259-271.
212. Soheili V, Bazzaz BS, Abdollahpour N, Hadizadeh F (2015) Investigation of Pseudomonas aeruginosa quorum-sensing signaling system for identifying multiple inhibitors using molecular docking and structural analysis methodology. Microb Pathog 89:73-78.
213. Stephenson K, Yamaguchi Y, Hoch JA (2000) The mechanism of action of inhibitors of bacterial two-component signal transduction systems. J Biol Chem 275:38900-38904.
214. Sturm A, Heinemann M, Arnoldini M, Benecke A, Ackermann M, Benz M, Dormann J, Hardt WD (2011) The cost of virulence: retarded growth of Salmonella Typhimurium cells expressing type III secretion system 1. PLoS Pathog 7:e1002143.
215. Sully EK, Malachowa N, Elmore BO, Alexander SM, Femling JK, Gray BM, DeLeo FR, Otto M, Cheung AL, Edwards BS et al (2014) Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog 10:e1004174.
216. Suzuki N, Ohtaguro N, Yoshida Y, Hirai M, Matsuo H, Yamada Y, Imamura N, Tsuchiya T (2015) A compound inhibits biofilm formation of Staphylococcus aureus from Streptomyces. Biol Pharm Bull 38:889-892.
217. Svensson M, Frendeus B, Butters T, Platt F, Dwek R, Svanborg C (2003) Glycolipid depletion in antimicrobial therapy. Mol Microbiol 47:453-461.
218. Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
219. Thanassi DG, Bliska JB, Christie PJ (2012) Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function. FEMS Microbiol Rev 36:1046-1082.
220. Toledo-Arana A, Dussurget O, Nikitas G, Sesto N, Guet-Revillet H, Balestrino D, Loh E, Gripenland J, Tiensuu T, Vaitkevicius K et al (2009) The Listeria transcriptional landscape from saprophytism to virulence. Nature 459:950-956.
221. Tonello F, Seveso M, Marin O, Mock M, Montecucco C (2002) Screening inhibitors of anthrax lethal factor. Nature 418:386.
222. Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR (2007) Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase. Biochemistry 46:8980-8987.
223. Trachtman H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DW, Weiss R, Kaskel FJ, Spitzer A, Hirschman GH et al (2003) Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290:1337-1344.
224. Tree JJ, Wang D, McInally C, Mahajan A, Layton A, Houghton I, Elofsson M, Stevens MP, Gally DL, Roe AJ (2009) Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157: H7. Infect Immun 77:4209-4220 Trokter M, Felisberto-Rodrigues C, Christie PJ, Waksman G (2014) Recent advances in the structural and molecular biology of type IV secretion systems. Curr Opin Struct Biol 27:16-23.
225. Tsou LK, Dossa PD, Hang HC (2013) Small molecules aimed at type III secretion systems to inhibit bacterial virulence. Medchemcomm 4:68-79.
226. Turk BE, Wong TY, Schwarzenbacher R, Jarrell ET, Leppla SH, Collier RJ, Liddington RC, Cantley LC (2004) The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat Struct Mol Biol 11:60-66.
227. Vakulskas CA, Potts AH, Babitzke P, Ahmer BM, Romeo T (2015) Regulation of bacterial virulence by Csr (Rsm) systems. Microbiol Mol Biol Rev 79:193-224.
228. Vanella de Cuetos EE, Fernandez RA, Bianco MI, Sartori OJ, Piovano ML, Luquez C, de Jong LI (2011) Equine botulinum antitoxin for the treatment of infant botulism. Clin Vaccine Immunol 18:1845-1849.
229. Vanier G, Sekizaki T, Dominguez-Punaro MC, Esgleas M, Osaki M, Takamatsu D, Segura M, Gottschalk M (2008) Disruption of srtA gene in Streptococcus suis results in decreased interactions with endothelial cells and extracellular matrix proteins. Vet Microbiol 127:417-424.
230. Veenendaal AK, Sundin C, Blocker AJ (2009) Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 191:563-570.
231. Vimberg V, Kuzma M, Stodulkova E, Novak P, Bednarova L, Sulc M, Gazak R (2015) Hydnocarpin-type Flavonolignans: semisynthesis and inhibitory effects on Staphylococcus aureus biofilm formation. J Nat Prod 78:2095-2103.
232. Vogel J, Luisi BF (2011) Hfq and its constellation of RNA. Nat Rev Microbiol 9:578-589.
233. Vogt SL, Raivio TL (2012) Just scratching the surface: an expanding view of the Cpx envelope stress response. FEMS Microbiol Lett 326:2-11.
234. Voth DE, Broederdorf LJ, Graham JG (2012) Bacterial type IV secretion systems: versatile virulence machines. Future Microbiol 7:241-257.
235. Waksman G, Orlova EV (2014) Structural organisation of the type IV secretion systems. Curr Opin Microbiol 17:24-31.
236. Wang D, Zetterstrom CE, Gabrielsen M, Beckham KS, Tree JJ, Macdonald SE, Byron O, Mitchell TJ, Gally DL, Herzyk P et al (2011) Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds. J Biol Chem 286:29922-29931.
237. Weber GG, Kortmann J, Narberhaus F, Klose KE (2014) RNA thermometer controls temperature-dependent virulence factor expression in Vibrio cholerae. Proc Natl Acad Sci USA 111:14241-14246.
238. Weigel WA, Demuth DR (2015) QseBC, a two component bacterial adrenergic receptor and global regulator of virulence in Enterobacteriaceae and Pasteurellaceae. Mol Oral Microbiol. doi:10.1111/omi.12138. [Epub ahead of print].
239. Westermann AJ, Gorski SA, Vogel J (2012) Dual RNA-seq of pathogen and host. Nat Rev Microbiol 10:618-630.
240. Wilke KE, Francis S, Carlson EE (2015) Inactivation of multiple bacterial histidine kinases by targeting the ATP-binding domain. ACS Chem Biol 10:328-335.
241. Wolf K, Betts HJ, Chellas-Gery B, Hower S, Linton CN, Fields KA (2006) Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol 61:1543-1555.
242. Wong AR, Pearson JS, Bright MD, Munera D, Robinson KS, Lee SF, Frankel G, Hartland EL (2011) Enteropathogenic and enterohaemorrhagic Escherichia coli: even more subversive elements. Mol Microbiol 80:1420-1438.
243. Worthington RJ, Blackledge MS, Melander C (2013) Small-molecule inhibition of bacterial two-component systems to combat antibiotic resistance and virulence. Future Med Chem 5:1265-1284.
244. Wright KJ, Hultgren SJ (2006) Sticky fibers and uropathogenesis: bacterial adhesins in the urinary tract. Future Microbiol 1:75-87.
245. Wright JS 3rd, Jin R, Novick RP (2005) Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad Sci USA 102:1691-1696.
246. Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Tang W, Bansal A, Cummings RT, Cunningham BR, Friedlander AM et al (2006) The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett 16:964-968.
247. Zahid MS, Awasthi SP, Asakura M, Chatterjee S, Hinenoya A, Faruque SM, Yamasaki S (2015) Suppression of virulence of toxigenic Vibrio cholerae by anethole through the cyclic AMP (cAMP)-cAMP receptor protein signaling system. PLoS ONE 10:e0137529.
248. Zambelloni R, Marquez R, Roe AJ (2015) Development of antivirulence compounds: a biochemical review. Chem Biol Drug Des 85:43-55.
249. Zetterstrom CE, Hasselgren J, Salin O, Davis RA, Quinn RJ, Sundin C, Elofsson M (2013) The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuber-culosis and Pseudomonas aeruginosa. PLoS ONE 8:e81969.
250. Zhang C, Zhang W (2010) Escherichia coli K88ac fimbriae expressing heat-labile and heat-stable (STa) toxin epitopes elicit antibodies that neutralize cholera toxin and STa toxin and inhibit adherence of K88ac fimbrial E. coli. Clin Vaccine Immunol 17:1859-1867.
251. Zhang J, Liu H, Zhu K, Gong S, Dramsi S, Wang YT, Li J, Chen F, Zhang R, Zhou L et al (2014) Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase. Proc Natl Acad Sci USA 111:13517-13522.